Home › Research › Treatments
Safety, Efficacy, and Feasibility of Intranasal Insulin for the Treatment of Mild Cognitive Impairment and Alzheimer Disease Dementia: A Randomized Clinical Trial
Craft S, Raman R, Chow TW, Rafii MS, Sun CK, Rissman RA, Donohue MC, Brewer JB et al.. JAMA neurology, 2020-09-01
Topic: Risk, prevention and care in population studies
Plain-language summary
Results A total of 289 participants (155 men [54.6%]; mean [SD] age, 70.9 [7.1] years) were randomized. No clinically important adverse events were associated with treatment.
What this study adds
Evidence grade: High
This is a trial of 432 participants. This randomized clinical trial of 289 participants found no clinically important adverse events associated with intranasal insulin treatment. Reported effect size: or 1.0; 54.6%; 51.3%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Craft, S., Raman, R., Chow, T. W., Rafii, M. S., Sun, C. K., Rissman, R. A., et al. (2020). Safety, Efficacy, and Feasibility of Intranasal Insulin for the Treatment of Mild Cognitive Impairment and Alzheimer Disease Dementia: A Randomized Clinical Trial. JAMA neurology. https://doi.org/10.1001/jamaneurol.2020.1840
Vancouver
Craft S, Raman R, Chow TW, Rafii MS, Sun CK, Rissman RA, et al. Safety, Efficacy, and Feasibility of Intranasal Insulin for the Treatment of Mild Cognitive Impairment and Alzheimer Disease Dementia: A Randomized Clinical Trial. JAMA neurology. 2020. doi:10.1001/jamaneurol.2020.1840. PMID: 32568367.
BibTeX
@article{craft2020-32568367,
author = {Craft, S. and Raman, R. and Chow, T. W. and Rafii, M. S. and Sun, C. K. and Rissman, R. A. and Donohue, M. C. and Brewer, J. B. and others},
title = {{Safety, Efficacy, and Feasibility of Intranasal Insulin for the Treatment of Mild Cognitive Impairment and Alzheimer Disease Dementia: A Randomized Clinical Trial}},
journal = {JAMA neurology},
year = {2020},
doi = {10.1001/jamaneurol.2020.1840},
pmid = {32568367},
url = {https://doi.org/10.1001/jamaneurol.2020.1840}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results A total of 289 participants (155 men [54.6%]; mean [SD] age, 70.9 [7.1] years) were randomized.
- No clinically important adverse events were associated with treatment.
Why it matters
This randomized clinical trial of 289 participants found no clinically important adverse events associated with intranasal insulin treatment. The available text reports only safety information, not whether the treatment improved cognition.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designclinical trial
- Participants432
- Effect sizeor 1.0; 54.6%; 51.3%
- Evidence strengthHigh
How this study scored 77/100
Published in a leading specialty journal, and it is a randomized controlled trial.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (JAMA neurology) |
| Journal's citation record | 2 / 4 | JAMA Neurology: journal h-index 235 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A randomized controlled trial (from PubMed type “Randomized Controlled Trial”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2020 — within 10 year(s) of the newest study here |
| Sample size | 2 / 4 | 432 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 1 / 2 | Randomized (as stated in the record) |
| Times cited | 6 / 7 | Cited 385 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 48.1 citations a year over 8 year(s) since 2020 |
| Impact for its field and year | 5 / 6 | Cited 25.7× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 10 other studies in this library |
| Still being cited | 3 / 4 | Cited 182 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Paul S. S Aisen: h-index 87 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of California San Diego: institution h-index 1,852 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 4 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 32568367) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 77 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1001/jamaneurol.2020.1840
- PubMed: 32568367
- Original source →
- Free full text: PubMed Central →
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
10 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Treatments from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.